Unknown molecular target of LEAC-102

The molecular target of LEAC-102 is currently unidentified, as the drug is a complex botanical extract derived from the medicinal fungus Antrodia cinnamomea. LEAC-102 is primarily composed of triterpenoids, including antcin B, antcin K, and antcin H, which are thought to be the active constituents responsible for its pharmacological profile. In clinical trials, LEAC-102 has demonstrated potent immunomodulatory effects, specifically the dose-dependent upregulation of programmed cell death-1 (PD-1) on CD4+ and CD8+ T cells and the significant elevation of natural killer (NK) cells, NKT cells, and dendritic cells. These findings suggest that LEAC-102 may enhance the body's innate and adaptive immune responses against tumors and other pathogens. Furthermore, research into Antrodia cinnamomea extracts indicates they can modulate key intracellular signaling pathways, such as the mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) pathways, which are involved in inflammation and cell survival. LEAC-102 is being developed as a potential therapeutic for cancer, liver disorders, and fatigue, with a Phase I study confirming its safety and tolerability in healthy volunteers.

Other names

Antrodia cinnamomea extract targetAC extract targetLEAC-102 target

LEAC-102 modulates the immune system by upregulating PD-1 expression on T cells and increasing the populations of NK cells, NKT cells, and dendritic cells. It also influences the MAPK and NF-κB signaling pathways.